Clinical Trial

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-05-09
Trial Details
NCT Number NCT06928376
Lead Sponsor Chinese PLA General Hospital
Collaborators: First Affiliated Hospital of Harbin Medical University, Yantai Yuhuangding Hospital, The General Hospital of Western Theater Command, 940 Hospital of the People's Liberation Army Joint Logistic Support Force, 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Jining First People's Hospital
Conditions Acute Myeloid Leukemia, First Line Therapy
Enrollment 160 participants
Start Date 2024-04-18
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08